MOGAD

1. Disease Information

1.1 Overview

MOGAD is "a rare, antibody-mediated inflammatory demyelinating disorder of the central nervous system (CNS) with various phenotypes starting from optic neuritis, via transverse myelitis to acute demyelinating encephalomyelitis (ADEM) and cortical encephalitis" (PMID: 33374173). The disease is defined by the presence of serum MOG-IgG detected by live cell-based assay (CBA), in the context of compatible clinical demyelinating events.

The 2023 international consensus diagnostic criteria established that "Serum antibodies directed against myelin oligodendrocyte glycoprotein (MOG) are found in patients with acquired CNS demyelinating syndromes that are distinct from multiple sclerosis and aquaporin-4-seropositive neuromyelitis optica spectrum disorder" (PMID: 36706773).

1.2 Key Identifiers

1.3 Synonyms and Alternative Names

• MOG antibody-associated disease (MOGAD)
• MOG-IgG-associated disorder
• Anti-MOG-associated disease
• MOG antibody disease
• MOG spectrum disorder
• Anti-MOG encephalomyelitis
• MOG-IgG-associated encephalomyelitis

1.4 Information Sources

This report is derived from aggregated disease-level resources including systematic reviews, meta-analyses, international multicenter cohort studies, population-based epidemiological studies, brain biopsy/autopsy series, and clinical trial data. A total of 142 papers were reviewed, with 21 confirmed findings supported by direct abstract citations.

2. Etiology

2.1 Disease Causal Factors

MOGAD is an autoimmune/antibody-mediated disease. The primary causal mechanism involves IgG1-class autoantibodies targeting MOG on the surface of oligodendrocytes and myelin sheaths, triggering:

1. Complement-dependent cytotoxicity (CDC): C3d and C5b-9 (membrane attack complex) deposition on myelin (PMID: 32048003)
2. Antibody-dependent cellular cytotoxicity (ADCC): Granulocytic and macrophage-mediated damage
3. CD4+ T-cell-mediated inflammation: Dominant inflammatory infiltrate in MOGAD lesions

The upstream trigger for MOG-IgG production remains incompletely understood but is believed to involve a combination of genetic susceptibility and environmental/infectious triggers.

2.2 Risk Factors

Genetic Risk Factors

MOGAD is not a Mendelian disorder. Unlike MS, where HLA-DRB1*15:01 is a well-established risk allele, MOGAD lacks confirmed genetic susceptibility loci. However:

• HLA associations: HLA-DQB106:02 and HLA-DRB115:01 have been associated with oligoclonal band-positive optic neuritis (PMID: 29544193), though these are more typical of MS
• MOG-IgG subclass: Most MOG antibodies are IgG1 subclass; rare cases with isolated MOG-IgG3 have been reported, sometimes in the context of IgG1 deficiency (PMID: 41406406)
• No GWAS loci have been confirmed for MOGAD specifically

Environmental Risk Factors

• Preceding infections: MOGAD is frequently preceded by infections. Sanderson et al. demonstrated that "MOG-specific B cells take up large amounts of MOG from cell membranes. When influenza hemagglutinin is also present in the membrane of the target cell, it can be cocaptured with MOG by MOG-specific B cells via the B-cell receptor" (PMID: 28057865). This molecular mimicry/bystander activation mechanism provides a plausible link between infection and autoimmunity.
• Age: Bimodal age distribution — peak in early childhood (ADEM phenotype) and in young adulthood (optic neuritis phenotype)
• Sex: Near-equal sex ratio, distinguishing MOGAD from MS (female predominance 3:1) and AQP4+ NMOSD (female predominance 9:1)
• Ethnicity/Race: Hispanic and non-White non-Hispanic adults may have increased risk of relapsing disease compared to non-Hispanic Whites (adjusted RR 1.52, 95% CI: 1.01–2.30) (PMID: 37979410)
• COVID-19: Reports suggest COVID-19 may trigger ADEM-associated optic neuritis presentations (PMID: 40728559)
• TNF-alpha inhibitors: Adalimumab (a TNF-alpha inhibitor) has been reported as a potential immunologic trigger for MOGAD/FLAMES (PMID: 41406158)

Protective Factors

• Pregnancy: Appears strongly protective. In a US two-center study, "No relapses were observed during any of the 22 pregnancies... The mean ARR was 0.26 during the 12-month pre-pregnancy period, 0 during pregnancy, and 0.09 in the 12-month postpartum period" (PMID: 41066906). However, "Three-quarters of women with previously monophasic disease transitioned to a relapsing course postpartum" (PMID: 41747756), indicating postpartum risk.

2.3 Gene-Environment Interactions

The cocapture mechanism described by Sanderson et al. (PMID: 28057865) represents a gene-environment interaction wherein viral antigens are cocaptured with MOG by MOG-specific B cells, leading to T-cell help from virus-specific T cells and class-switched anti-MOG antibody production. This suggests that common infections may break tolerance in genetically susceptible individuals.

3. Phenotypes

3.1 Core Clinical Phenotypes

MOGAD presents with age-dependent clinical phenotypes:

"Typical MOGAD presentations consist of demyelinating syndromes, including acute disseminated encephalomyelitis (ADEM) in younger, and optic neuritis (ON) and/or transverse myelitis (TM) in older children" (PMID: 33162302).

"The most frequent presentations were optic neuritis in adults (62.3%) and ADEM in children (34.8%); 64.5% had a monophasic disease course over a median follow-up of 38 months" (PMID: 41657079).

3.2 Optic Neuritis

MOGAD optic neuritis is characterized by: - Severe acute vision loss but better recovery than MS-ON: "significantly worse visual acuity at nadir, but better recovery and thinner global peripapillary retinal nerve fiber layer thickness in MOG-ON patients compared to MS-ON patients" (PMID: 32785840) - Attack-dependent retinal damage without progressive neurodegeneration: "the absence of attack-independent retinal damage in patients with MOGAD. Yet, ongoing neuroaxonal damage or edema resolution seems to occur for up to 12 months after ON" (PMID: 35703428) - Perineural enhancement on MRI: most common MRI finding (40.3%) (PMID: 42070455) - Bilateral involvement more common than in MS - pRNFL thinning rate: 0.35 μm/year (95% CI 0.04–0.66)

3.3 Myelitis

MOGAD myelitis features include: - H-sign (gray matter involvement): present in 63% (PMID: 37060644) - Longitudinally extensive transverse myelitis (LETM): 63% - Leptomeningeal enhancement: 61% (PMID: 41252657) - Conus medullaris predilection (PMID: 35785363) - Symptoms: weakness (91%), neurogenic bladder (63%), sensory dysfunction (46%)

3.4 Cognitive Impairment

Adults with MOGAD show "mild global cognitive impairment, with pooled MoCA scores of 24.69 (95% CI: 23.31–26.07). Processing speed and working memory were consistently affected, with pooled PASAT-3 means of 39.14 (95% CI: 35.68–42.61), PASAT-2 of 30.91 (95% CI: 28.08–33.75), and SDMT of 44.47 (95% CI: 41.73–47.20)" (PMID: 41831288). Pediatric cohorts showed relative preservation (FSIQ: 98.93).

Suggested HPO terms: HP:0100543 (Cognitive impairment), HP:0031843 (Processing speed impairment)

3.5 Patient-Reported Outcomes

Qualitative interviews revealed that "The most common patient-reported symptoms were eye pain, fatigue, body aches/pain, headaches, and blurred vision. Eye pain and body aches/pain were reported as the most bothersome symptoms and most important to improve with treatment" (PMID: 40506564). Quality-of-life impacts include difficulty with household chores, inability to work, depression, and difficulty walking.

3.6 FLAMES (FLAIR-hyperintense Lesions in Anti-MOG-associated Encephalitis with Seizures)

A distinctive cortical encephalitis phenotype characterized by: - Unilateral cortical FLAIR hyperintensities (predominantly frontal lobe) - Seizures (focal seizures predominant) - Headache and altered mental status - Good immunotherapy response - Prevalence: 7.3% of pediatric MOGAD (PMID: 40740785)

3.7 Overlap Syndromes

MOG-NMDAR overlap syndrome: A highly relapsing dual-antibody phenotype with 100% relapse rate (mean interval 6.7 months), 80% cortical encephalopathies, CSF pleocytosis in 90% (PMID: 39780343).

4. Genetic/Molecular Information

4.1 Target Autoantigen: MOG

MOGAD is not a genetic/Mendelian disease. There are no causal gene mutations or pathogenic variants in the classical sense. The disease is driven by autoantibodies against:

• MOG gene (HGNC: 7197; NCBI Gene ID: 4340; UniProt: Q16653)
• Located on chromosome 6p22.1 within the HLA complex
• Encodes myelin oligodendrocyte glycoprotein, a type I transmembrane protein exclusively expressed on the outermost surface of CNS myelin and oligodendrocyte membranes
• MOG constitutes ~0.05% of total myelin protein but its extracellular location makes it accessible to circulating antibodies
• GO terms: GO:0043209 (myelin sheath), GO:0007399 (nervous system development), GO:0042552 (myelination)

4.2 Autoantibody Characteristics

• Primary subclass: IgG1 (most common and pathogenic)
• Rare subclass: IgG3 (isolated cases; PMID: 41406406)
• Detection: Live cell-based assay (CBA) is the gold standard; fixed CBA has lower sensitivity
• MOG-IgG titer correlates with disease activity; seroconversion (becoming negative) is associated with monophasic course
• Caution needed with low-positive results (PMID: 38043365)

4.3 Genetic Susceptibility

• (TAAA)n polymorphism in the 3' flanking region of the MOG gene: The 226 bp allele has been associated with anti-MOG antibody positivity (PMID: 12576235)
• HLA associations: Not firmly established for MOGAD specifically, unlike MS (HLA-DRB1*15:01)
• No GWAS studies have been performed specifically for MOGAD

4.4 Epigenetic Information

Limited data available. No systematic studies of DNA methylation, histone modifications, or chromatin changes specific to MOGAD have been published. This represents a significant knowledge gap.

5. Environmental Information

5.1 Infectious Triggers

MOGAD is "frequently preceded by infections" (PMID: 39295869). The molecular mechanism involves:

1. MOG-specific B cells capture MOG from cell membranes
2. If viral antigens (e.g., influenza hemagglutinin) are present in the same membrane, they are cocaptured
3. This leads to T-cell help from virus-specific T cells, driving class-switched anti-MOG antibody production (PMID: 28057865)

Reported infectious triggers include upper respiratory tract infections (most common), COVID-19 (PMID: 40728559), syphilis and HIV (PMID: 39295869; PMID: 40766314).

5.2 Iatrogenic Triggers

TNF-alpha inhibitors (adalimumab): Case reports of MOGAD/FLAMES following TNF-alpha inhibitor therapy for psoriasis (PMID: 41406158).

5.3 Seasonal Patterns

A Latin American cohort analysis found fewer relapses in autumn (N=21, 17%; IRR 0.17, 95% CI 0.11–0.25, p=0.001) and a peak in November, but circular statistics did not confirm a consistent seasonal pattern (PMID: 41167050).

6. Mechanism / Pathophysiology

6.1 Causal Chain: From Trigger to Clinical Manifestation

UPSTREAM TRIGGERS
    │
    ├── Preceding infection (molecular mimicry / bystander activation)
    ├── Genetic susceptibility (HLA? MOG gene polymorphisms?)
    └── Environmental triggers (TNF-alpha inhibitors, vaccines?)
    │
    ▼
IMMUNE ACTIVATION
    │
    ├── B-cell activation → MOG-specific B cells capture MOG + viral antigens
    ├── T-cell help from virus-specific T cells → class-switched anti-MOG IgG1
    └── CD4+ T-cell priming against MOG epitopes
    │
    ▼
AUTOANTIBODY-MEDIATED DAMAGE
    │
    ├── MOG-IgG1 binds MOG on oligodendrocyte/myelin surface
    ├── Complement activation → C3d + C5b-9 (MAC) deposition
    ├── Complement-dependent cytotoxicity (CDC)
    ├── Antibody-dependent cellular cytotoxicity (ADCC)
    └── Granulocyte and macrophage recruitment
    │
    ▼
TISSUE PATHOLOGY
    │
    ├── Perivenous demyelination (92% of lesions) — ADEM-like pattern
    ├── CD4+ T-cell dominated inflammation
    ├── Variable axonal damage (correlates with cerebral atrophy)
    ├── Preserved AQP4 expression (no astrocytopathy)
    └── No slowly expanding "smoldering" lesions (unlike MS)
    │
    ▼
CLINICAL MANIFESTATION
    │
    ├── Optic neuritis (adults) → severe acute vision loss, perineural enhancement
    ├── ADEM (children) → encephalopathy with multifocal white matter lesions
    ├── Transverse myelitis → H-sign, LETM, conus predilection
    ├── Cortical encephalitis/FLAMES → seizures, unilateral cortical FLAIR
    └── Brainstem syndromes → cranial neuropathies
    │
    ▼
DISEASE COURSE
    │
    ├── Monophasic (50-64%) if MOG-IgG becomes negative (seroconversion)
    └── Relapsing (36-50%) if MOG-IgG persists
        Disability is relapse-dependent, NOT progressive

6.2 Histopathology

The neuropathological hallmark was defined by Höftberger et al.: "MOGAD pathology is dominated by coexistence of both perivenous and confluent white matter demyelination, with an over-representation of intracortical demyelinated lesions compared to typical MS. Radially expanding confluent slowly expanding smoldering lesions in the white matter as seen in MS, are not present. A CD4+ T-cell dominated inflammatory reaction with granulocytic infiltration predominates. Complement deposition is present in all active white matter lesions, but a preferential loss of MOG is not observed. AQP4 is preserved, with absence of dystrophic astrocytes" (PMID: 32048003).

Systematic brain biopsy analysis confirmed: "Most demyelinating lesions in 10 of 11 cases showed a perivenous demyelinating pattern previously reported in ADEM (153/167 lesions) and a fusion pattern (11/167 lesions)" (PMID: 32412053). Variable axonal damage was observed, correlating with cerebral atrophy (PMID: 39267735).

6.3 Comparative Pathology

6.4 Molecular Pathways and Cell Types

6.5 Biomarker Profiling

• sNfL: Elevated during attacks (median 16.0 pg/mL in MOGAD-ON vs 6.5 in controls, p<0.001); nonlinearly associated with time from attack onset (PMID: 39705633; PMID: 41032997)
• sGFAP: Less specific for MOGAD than for AQP4+ NMOSD (PMID: 33933106)
• TNF-alpha and alphaB-crystallin: Upregulated during antibody-mediated demyelination, potentially protective (PMID: 15478179)

7. Anatomical Structures Affected

7.1 Organ and System Level

7.2 Tissue and Cell Level

• Myelin sheaths: Primary target of MOG-IgG-mediated demyelination
• Oligodendrocytes (CL:0000128): MOG-expressing cells; variable destruction
• Neurons: Generally preserved acutely; variable axonal damage
• Astrocytes: Preserved (AQP4 expression maintained — key distinction from AQP4+ NMOSD)

7.3 Lateralization

• Optic neuritis: Can be unilateral or bilateral (bilateral more common than in MS)
• FLAMES: Characteristically unilateral cortical involvement
• Myelitis: Central cord involvement (H-sign on axial MRI)

8. Temporal Development

8.1 Onset

• Typical age of onset: Bimodal — childhood peak (median ~5–9 years for ADEM) and adult peak (median ~30–40 years for ON)
• Onset pattern: Acute to subacute (days to weeks)
• Pediatric MOGAD median onset: 5.7 years for ADEM, 8.9 years for encephalitis (PMID: 39393046)

8.2 Disease Course

"The disease followed a multiphasic course in 80% (median time-to-first-relapse 5 months; annualized relapse rate 0.92) and resulted in significant disability in 40% (mean follow-up 75 ± 46.5 months)" (PMID: 27793206).

8.3 MRI Lesion Dynamics

A critical distinguishing feature is T2 lesion resolution: "Resolution of at least one T2-lesion differentiated MOGAD from MS (sensitivity 77–100%, specificity 86–99%; Youden's index=0.90)" (PMID: 40685157). MOGAD patients are more likely to have normal MRI at follow-up vs MS (brain: 32% vs 0%, p<0.001; spine: 78% vs 19%, p<0.001).

8.4 Critical Periods

• Early treatment window: Early treatment of first attack (<5 days) is associated with higher likelihood of MOG-IgG seroconversion and potentially reduced relapse risk (PMID: 39226035)
• Postpartum period: Window of increased relapse vulnerability; three-quarters of previously monophasic women transitioned to relapsing course postpartum (PMID: 41747756)

9. Inheritance and Population

9.1 Epidemiology

MOGAD incidence/prevalence is approximately 3× higher than AQP4+ NMOSD.

9.2 Inheritance Pattern

MOGAD is not inherited in a Mendelian pattern. It is an acquired autoimmune disease with complex (multifactorial/polygenic) susceptibility.

9.3 Population Demographics

• Sex ratio: Near-equal (approximately 1:1) — "Sex ratio was almost equal in males and females" (PMID: 41657079)
• Geographic/ethnic variation: Japanese patients have lower ARR (0.4 vs 0.8, p=0.019) and more monophasic course (64% vs 25%, p=0.002) compared to German patients (PMID: 33219036)
• Age distribution: Affects all ages from infancy to late adulthood; peak incidence 18–39 years

10. Diagnostics

10.1 2023 International Diagnostic Criteria

The 2023 MOGAD criteria (PMID: 36706773) require: 1. Core clinical demyelinating event (ON, myelitis, ADEM, cerebral cortical encephalitis, brainstem/cerebellar syndrome) 2. Positive serum MOG-IgG by CBA 3. For low-titer positivity: additional supportive clinical and MRI features required

Validation yielded 100% sensitivity and 55.5% specificity in one institutional cohort (PMID: 38043365).

10.2 CSF Analysis

"Most strikingly, CSF-restricted oligoclonal IgG bands, a hallmark of multiple sclerosis (MS), were absent in almost 90% of samples (N=151), and the MRZ reaction, the most specific laboratory marker of MS known so far, in 100% (N=62)" (PMID: 32883348).

10.3 Neuroimaging

Brain MRI

MOGAD-specific features (PMID: 40773034): - Conus medullaris T2 lesions, "fluffy" lesions, perineural enhancement - Peri-ependymal 3rd and 4th ventricle T2 lesions - T2 lesion resolution over time - Absence of Dawson's fingers, periventricular ovoid lesions - No paramagnetic rim lesions (PRLs) — supports discrimination from MS (PMID: 41512208)

MRI brain lesion distribution criteria distinguish RRMS from MOGAD with 95.2% specificity (PMID: 27951522).

Spinal MRI

• H-sign (gray matter, 63%), LETM (63%), leptomeningeal enhancement (61%)
• Conus medullaris predilection (PMID: 37060644; PMID: 41252657)

10.4 Optical Coherence Tomography (OCT)

• Attack-dependent retinal damage without progressive inter-attack neurodegeneration (PMID: 35703428)
• Acute RNFL thickening followed by steady thinning; structure-function paradox in recovery (PMID: 38526582)

10.5 Serum Biomarkers

10.6 Visual Evoked Potentials (VEP)

"Ancillary investigations such as visual fields, visual evoked potentials and cerebrospinal fluid analysis may be less discriminatory" than MRI and OCT for MOG-ON diagnosis (PMID: 38783085).

10.7 Differential Diagnosis

11. Outcome / Prognosis

11.1 Long-Term Disability

"The disease resulted in significant disability in 40% (mean follow-up 75 ± 46.5 months), with severe visual impairment or functional blindness (36%) and markedly impaired ambulation due to paresis or ataxia (25%) as the most common long-term sequelae" (PMID: 27793206).

11.2 Geographic/Ethnic Variation

"Japanese patients had a lower annualised relapse rate (0.4 vs 0.8, p=0.019; no relapse, 64% vs 25%, p=0.002) and lower Expanded Disability Status Scale score at the last visit (1.0 vs 2.0)" compared to German patients (PMID: 33219036).

11.3 Prognostic Factors

11.4 Survival

MOGAD is generally not fatal. Life expectancy is believed to be near-normal with appropriate treatment, though severe attacks involving the brainstem can rarely be life-threatening.

12. Treatment

12.1 Acute Attack Treatment

First-line: High-dose IV methylprednisolone (1g/day for 3–5 days) — chosen by 84.1% of neurologists (PMID: 40584638) - MAXO: MAXO:0001298 (corticosteroid therapy)

Second-line (steroid-refractory): - Plasma exchange (PLEX): Level II evidence for improved visual outcomes in acute ON (PMID: 41670578) — MAXO:0000602 - IVIG: Alternative rescue therapy — MAXO:0000571

12.2 Maintenance/Relapse Prevention

The meta-analysis by Thakolwiboon et al. compared steroid-sparing therapies: "Relapse probabilities and pooled mean ARR during therapies were as follows: AZA 53.1% [ARR 0.291], MMF 38.5% [ARR 0.836], RTX 48.9% [ARR 0.629], and mIVIG 25.3% [ARR 0.081]" (PMID: 34634625).

Pediatric data confirm IVIG superiority: "13% of patients with IVIG relapsed in the first year, compared to 33% in the IMT group (relative risk 0.70, 95% CI 0.53–0.99, p=0.061); HR for early relapse 0.36 (95% CI 0.15–0.87, p=0.023)" (PMID: 41092852).

Adult multicenter IVIG data: median ARR decreased from 1.4 pre-treatment to 0 on IVIG (p<0.001). Higher doses (≥1 g/kg q4w) associated with lower relapse risk (HR 3.31 for lower dosing, p=0.02) (PMID: 35377395).

12.3 Treatment Strategy Considerations

A critical treatment challenge: up to 50% of patients have monophasic disease and may not need maintenance therapy. "Sustained immunosuppression may not be required for all patients with MOGAD, whereas AQP4+NMOSD typically demands continuous therapy" (PMID: 41927387).

Early treatment window: Treatment of first attack within <5 days may promote MOG-IgG seroconversion and reduce long-term relapse risk (PMID: 39226035).

12.4 Emerging and Experimental Therapies

CAR T-cell therapy represents an emerging transformative approach: "These conditions are driven in part by autoreactive B cells that sustain chronic inflammation and progressive tissue damage. While current immunomodulatory therapies have improved clinical outcomes, they often require lifelong administration and fail to effectively eliminate compartmentalized inflammation within the central nervous system" (PMID: 41470000).

12.5 Supportive and Rehabilitative Care

• Visual rehabilitation for patients with persistent visual impairment
• Physical therapy for motor disability from myelitis (MAXO:0000011)
• Cognitive rehabilitation for processing speed and working memory deficits
• Pain management (eye pain and body aches are the most bothersome symptoms)
• Psychological support for depression and work/school disruption

13. Prevention

13.1 Primary Prevention

No established primary prevention strategies exist for MOGAD. Avoidance of known triggers (e.g., TNF-alpha inhibitors) in susceptible individuals may be considered.

13.2 Secondary Prevention (Early Detection)

• MOG-IgG testing recommended in patients with bilateral ON, ADEM, LETM, cortical encephalitis, or atypical MS presentations
• 90.5% of neurologists send serum MOG-IgG after first demyelinating event (PMID: 40584638)
• 2024 revised McDonald MS criteria recommend MOG-IgG testing in children <12 years (PMID: 40975101)

13.3 Tertiary Prevention (Relapse Prevention)

• Maintenance IVIG is the most effective relapse prevention strategy
• Regular monitoring of visual function, motor function, and cognitive function
• Postpartum monitoring is critical given the increased relapse risk (PMID: 41747756)
• Pregnancy counseling: CD20 antibodies increasingly used around pregnancy with promising safety data (PMID: 41925496)

14. Other Species / Natural Disease

14.1 Natural Disease

No naturally occurring MOGAD equivalent has been described in companion animals or wildlife. MOG is conserved across mammals, but spontaneous anti-MOG autoimmunity has not been documented outside humans.

14.2 Orthologous Genes

• Mouse MOG: NCBI Gene ID 17441 (Mus musculus, NCBI Taxon: 10090)
• Rat MOG: NCBI Gene ID 24558 (Rattus norvegicus, NCBI Taxon: 10116)
• Marmoset MOG: Ortholog present (Callithrix jacchus, NCBI Taxon: 9483)

15. Model Organisms

15.1 Mouse MOG-EAE Models

• MOG35-55 peptide-induced EAE (C57BL/6): T-cell-mediated model; does not require B cells
• Recombinant MOG protein-induced EAE: B-cell-dependent model; better recapitulates antibody-mediated aspects
• B-cell depletion exacerbates peptide EAE but ameliorates protein EAE (PMID: 20641064)
• Early mitochondrial dysfunction at synapses (day 5 post-injection) precedes clinical signs (PMID: 41898442)

15.2 Marmoset MOG-EAE Model

"MOG-induced EAE in common marmoset monkeys reflects one specific lesional subtype of MS, namely MS pattern II lesions with antibody/complement-mediated damage" (PMID: 16900750). CD20+ B-cell depletion "profoundly reduced the development of both white and gray matter lesions" (PMID: 22002426). This is the best available model for antibody-mediated demyelination in MOGAD.

15.3 In Vitro Models

Rat telencephalon aggregate cultures: Antibody-mediated demyelination with MOG antibodies + complement, showing demyelination without cell death and protective TNF-alpha/alphaB-crystallin upregulation (PMID: 15478179).

15.4 Model Limitations

• Mouse peptide EAE is primarily T-cell-driven and does not fully recapitulate antibody-mediated pathology
• No animal model perfectly reproduces the monophasic vs. relapsing dichotomy
• Marmoset EAE is more translational but expensive and limited by availability
• MOG-EAE does not capture the age-dependent phenotype spectrum (ADEM vs. ON)

15.5 Translational Applications

MOG-EAE models have directly informed treatment approaches including corticosteroids, PLEX, IVIG, complement inhibition, and B-cell depletion strategies (PMID: 40463369). Novel remyelination compounds (bavisant, morusin) have been identified through EAE screening (PMID: 41564155; PMID: 41828535).

Evidence Base: Key Literature

Landmark Papers

Limitations and Knowledge Gaps

1. No GWAS or comprehensive genetic studies for MOGAD susceptibility — the genetic architecture is entirely unknown
2. No epigenetic data — no studies of DNA methylation, histone modifications, or chromatin states in MOGAD
3. No FDA-approved MOGAD-specific therapy — all treatments are off-label or in clinical trials
4. Biomarker gaps — no validated biomarker reliably predicts monophasic vs. relapsing course at onset
5. Limited multi-omics profiling — transcriptomic, proteomic, and metabolomic signatures largely uncharacterized
6. Pediatric treatment data — most evidence from retrospective studies; RCTs in children lacking
7. Ethnic/geographic heterogeneity — significant variation in prognosis between populations (Japanese vs. European) is unexplained
8. Overlap syndromes — biology and optimal management of MOG-NMDAR overlap poorly understood
9. Long-term outcomes — follow-up limited to 5–10 years in most cohorts
10. Cognitive impairment mechanisms — pathophysiology of processing speed/working memory deficits not elucidated
11. Animal model limitations — no single EAE model recapitulates all aspects of human MOGAD
12. Pharmacogenomics — no pharmacogenomic data exist for MOGAD treatments

Proposed Follow-up Experiments and Actions

Near-Term (1–2 years)

1. GWAS study of MOGAD: Recruit large international cohorts (N>1,000) to identify genetic susceptibility loci
2. Longitudinal biomarker validation: Prospective studies correlating serial sNfL, sGFAP, and MOG-IgG titers with relapse risk
3. RCT completion and analysis: Monitor outcomes of ongoing Phase 3 trials (satralizumab NCT05271273, rozanolixizumab NCT05063162, ravulizumab NCT05545826)
4. Single-cell transcriptomic profiling: Characterize immune cell populations in MOGAD CSF and blood during attacks vs. remission

Medium-Term (2–5 years)

1. Epigenomic profiling: DNA methylation and chromatin accessibility studies in MOGAD patient immune cells
2. CAR T-cell therapy trials: Controlled trials of CD19-directed CAR T-cell therapy for refractory MOGAD
3. Antigen-specific tolerance induction: Advance OM-MOG35-55 through Phase 1/2 trials
4. Multi-omics integration: Combine transcriptomics, proteomics, and metabolomics for comprehensive molecular models
5. Pregnancy management protocols: Develop evidence-based guidelines for treatment during pregnancy and postpartum

Long-Term (5+ years)

1. Precision medicine framework: Genotype-informed and biomarker-guided treatment algorithms
2. Natural history registries: International registries with >20-year follow-up
3. Improved animal models: Humanized mouse models expressing human MOG-IgG1

Ontology Term Summary

HPO (Human Phenotype Ontology)

HP:0100653 (Optic neuritis) | HP:0100510 (Transverse myelitis) | HP:0007305 (CNS demyelination) | HP:0001298 (Encephalopathy) | HP:0001250 (Seizures) | HP:0100543 (Cognitive impairment) | HP:0000572 (Visual loss) | HP:0003470 (Paralysis) | HP:0012378 (Fatigue) | HP:0012531 (Pain) | HP:0012229 (CSF pleocytosis)

GO (Gene Ontology)

GO:0043209 (Myelin sheath) | GO:0042552 (Myelination) | GO:0006958 (Complement activation, classical pathway) | GO:0042110 (T cell activation) | GO:0050853 (B cell receptor signaling) | GO:0006955 (Immune response) | GO:0005886 (Plasma membrane)

CL (Cell Ontology)

CL:0000128 (Oligodendrocyte) | CL:0000624 (CD4+ T cell) | CL:0000236 (B cell) | CL:0000094 (Granulocyte) | CL:0000235 (Macrophage)

UBERON (Anatomical Ontology)

UBERON:0000941 (Optic nerve) | UBERON:0002240 (Spinal cord) | UBERON:0002316 (White matter) | UBERON:0000956 (Cerebral cortex) | UBERON:0002298 (Brainstem) | UBERON:0003833 (Conus medullaris) | UBERON:0000966 (Retina)

CHEBI (Chemical Entities)

CHEBI:6888 (Methylprednisolone) | CHEBI:64357 (Rituximab) | CHEBI:168396 (Tocilizumab) | CHEBI:2948 (Azathioprine) | CHEBI:168612 (Mycophenolate mofetil)

MAXO (Medical Action Ontology)

MAXO:0001298 (Corticosteroid therapy) | MAXO:0000602 (Plasmapheresis) | MAXO:0000571 (IVIG therapy) | MAXO:0000780 (B-cell depletion therapy) | MAXO:0001001 (Immunosuppressive therapy)

MONDO

MONDO:0100475 (MOG antibody-associated disease)

Report generated from systematic review of 142 publications with 21 confirmed findings supported by direct abstract citation evidence across 5 investigation iterations. This comprehensive disease characterization covers all 15 sections of the disease knowledge base template with ontology-annotated entries suitable for database population.